Scientist

Scientist / Senior Scientist, Virology

Location: West London (Hybrid)

Company: RQ Bio

Sector: Biotechnology | Virology | Infectious Diseases | Antibody Therapeutics

Help develop the next generation of protection against influenza.

RQ Bio is an innovative, clinical-stage-focused biotechnology company developing long-acting monoclonal antibodies (LAAbs) designed to provide powerful, broad and durable protection against influenza, particularly for vulnerable and immunocompromised patients.

Following an oversubscribed £85.5 million ($115 million) Series A investment, backed by leading global life sciences investors including Frazier Life Sciences, Forbion and LifeArc Ventures, RQ Bio is entering an exciting phase of growth.

Its lead programme, RQB01, is advancing through IND-enabling studies, with the ambition of delivering season-long influenza protection through a single administration. Alongside this, RQ Bio is advancing a next-generation pipeline of antibody therapeutics targeting respiratory viral diseases.

We are now seeking a Scientist or Senior Scientist in Virology to help drive these programmes towards clinical development.

The opportunity

Reporting to the Head of R&D, you will play a key role in designing and delivering virology studies supporting antibody discovery and preclinical development.

Key responsibilities include:

• Design, develop and optimise viral infectivity and neutralisation assays.
• Lead virology studies, including in vitro and in vivo efficacy assessments.
• Manage external CROs, overseeing study design, execution, quality and delivery.
• Analyse complex experimental data and translate findings into programme decisions.
• Collaborate with multidisciplinary R&D teams to advance antibody discovery and development.
• Contribute to regulatory submissions, scientific publications and programme strategy.

What we're looking for

• PhD or equivalent experience in Virology, Immunology, Molecular Biology or a related discipline.
• Strong practical experience working with live viruses, pseudoviruses or viral vectors at CL2.
• Demonstrable experience developing and troubleshooting cell-based viral infectivity and/or neutralisation assays.
• Experience designing and managing outsourced studies through CROs or external partners.
• Strong experimental design, data interpretation and problem-solving capabilities.
• Practical knowledge of mammalian cell culture and molecular biology techniques.

Desirable: Influenza or respiratory virus expertise, preclinical drug development, in vivo efficacy studies, monoclonal antibody research and GxP-regulated studies.

Why join RQ Bio?

• £85.5m Series A funding supporting ambitious clinical development plans.
• Differentiated antibody technology designed to address a significant unmet medical need.
• Exciting pipeline spanning lead candidate development and next-generation antibody discovery.
• Scientific ownership and impact within an experienced, collaborative biotechnology team.
• Competitive salary and benefits, including pension, health insurance and hybrid working.

This is an opportunity to contribute directly to innovative antiviral programmes at a pivotal stage in their development.

Interested? Apply through LinkedIn to learn more about the opportunity.

Applicants should have the right to work in the UK or eligibility to obtain it.